TY - JOUR
T1 - Rhenium-188 for inhibition of human aortic smooth muscle cell proliferation
AU - Wiskirchen, Jakub
AU - Dittmann, Helmut
AU - Kehlbach, Rainer
AU - Vogel-Claussen, Jens
AU - Gebert, Regina
AU - Dohmen, Bernhard M.
AU - Schöber, Wolfgang
AU - Bares, Roland
AU - Rodemann, H. Peter
AU - Claussen, Claus D.
AU - Duda, Stephan H.
N1 - Funding Information:
Stephan H. Duda, Roland Bares, and H. Peter Rodemann were supported by Grant No. Du 301/3-1 from the German Research Society (Deutsche Forschungsgemeinschaft), Bonn, Germany.
PY - 2001/3/1
Y1 - 2001/3/1
N2 - Purpose: To evaluate dose-dependent growth-modulating effects of the β-γ emitter Rhenium-188 on cultured human aortic smooth muscle cells (haSMC). Methods and Materials: HaSMC were plated in 25 cm2 flasks. Two days after plating, cells were incubated with the Re-188 (beta Emax 2.12 MeV, tissue rangemax < 10 mm, T1/2 17 h) for five days. The doses administered were 0.2 Gy, 1, 4, 6, 8, 16, and 32 Gy. After five days, the radionuclide was removed. Cell growth, cell cycle distribution, and clonogenic activity were analyzed for the following 25 days. Results: The 0.2 and 1 Gy groups did not show relevant growth-inhibiting effects compared to the control groups. The 4 to 32 Gy groups presented dose-dependent growth inhibition, with a complete growth arrest of the 16 and 32 Gy groups. Clonogenic activity of the smooth muscle cell was strongly inhibited from doses ≥8 Gy. Flow cytometry showed a lasting dose-dependent G2/M phase block. Conclusion: Smooth muscle cell (SMC) growth can be controlled effectively with Re-188 for at least 25 days after radiation in vitro. As the first four weeks after arterial angioplasty are crucial concerning neointimal formation, Re-188 may be a valuable radionuclide to inhibit restenosis after arterial angioplasty.
AB - Purpose: To evaluate dose-dependent growth-modulating effects of the β-γ emitter Rhenium-188 on cultured human aortic smooth muscle cells (haSMC). Methods and Materials: HaSMC were plated in 25 cm2 flasks. Two days after plating, cells were incubated with the Re-188 (beta Emax 2.12 MeV, tissue rangemax < 10 mm, T1/2 17 h) for five days. The doses administered were 0.2 Gy, 1, 4, 6, 8, 16, and 32 Gy. After five days, the radionuclide was removed. Cell growth, cell cycle distribution, and clonogenic activity were analyzed for the following 25 days. Results: The 0.2 and 1 Gy groups did not show relevant growth-inhibiting effects compared to the control groups. The 4 to 32 Gy groups presented dose-dependent growth inhibition, with a complete growth arrest of the 16 and 32 Gy groups. Clonogenic activity of the smooth muscle cell was strongly inhibited from doses ≥8 Gy. Flow cytometry showed a lasting dose-dependent G2/M phase block. Conclusion: Smooth muscle cell (SMC) growth can be controlled effectively with Re-188 for at least 25 days after radiation in vitro. As the first four weeks after arterial angioplasty are crucial concerning neointimal formation, Re-188 may be a valuable radionuclide to inhibit restenosis after arterial angioplasty.
KW - Arteries-angioplasty
KW - Arteries-radiation
KW - Arteries-restenosis
UR - http://www.scopus.com/inward/record.url?scp=0035283674&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0035283674&partnerID=8YFLogxK
U2 - 10.1016/S0360-3016(00)01452-8
DO - 10.1016/S0360-3016(00)01452-8
M3 - Article
C2 - 11172964
AN - SCOPUS:0035283674
SN - 0360-3016
VL - 49
SP - 809
EP - 815
JO - International Journal of Radiation Oncology Biology Physics
JF - International Journal of Radiation Oncology Biology Physics
IS - 3
ER -